The factors that affect the price of CVAC.US (CureVac N.V.) stock include: Clinical Trial Results: Positive or negative data from CureVac's clinical trials for its mRNA-based therapies, especially vaccine candidates, significantly impacts investor sentiment and stock price.

Regulatory Approvals: Decisions by regulatory bodies like the EMA or FDA regarding the approval of CureVac's products directly influence its commercial prospects and stock valuation.

Partnerships and Collaborations: Agreements with pharmaceutical companies or research institutions can boost investor confidence and financial resources, driving the stock price up.

Financial Performance: CureVac's revenue, expenses, and cash flow influence investor perceptions of its financial stability and future profitability.

Market Sentiment: Overall market trends, investor risk appetite, and broader sentiment towards the biotechnology sector affect CureVac's stock price.

Competition: The success of competing mRNA vaccine technologies and therapies from companies like Moderna and BioNTech can impact CureVac's market position and stock value.

Intellectual Property: The strength and breadth of CureVac's patent portfolio play a crucial role in protecting its innovations and influencing its competitive advantage.

Manufacturing Capacity: CureVac's ability to scale up manufacturing to meet potential demand for its products is a key factor affecting its commercial success and stock price.

Management Team: The experience and expertise of CureVac's leadership team influence investor confidence in the company's strategic direction and execution capabilities.

Global Health Crises: Events like pandemics can significantly increase demand for vaccines and therapies, impacting CureVac's stock price.

Alternative Investments: Interest rate and investment availability can affect investors preference.